Eribulin

HALAVEN®

Antineoplastic landscape

About HALAVEN®

  1. Marketed by Eisai Inc.
  2. Microtubule dynamics inhibitor
  3. Treatment of refractory, metastatic breast cancer and liposarcoma

Approvals

  1. First U.S. approval: November 15, 2010
  2. First E.U. approval: March 17, 2011

Constraint date forecast:

  1. Patent expiry: 2023 (United States)
  2. SPC expiry: 2024 (European Union)
  3. Patent expiry: 2024 (Japan)

API availability

Source: Cortellis Generics Intelligence

The future of the generics landscape

Drugs to Watch
Drugs to Watch
Drugs to Watch
Drugs to Watch

From innovation to bottom line

Access our global intelligence, advanced analytics and global team of experts.

Contact our team